Study details
Enrolling now
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
University of California, Irvine
NCT IDNCT06682728ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
23
Study length
about 2 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing a treatment with Sacituzumab Govitecan and Nivolumab for people who have muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract. The goal is to see if this combination helps prevent cancer from coming back after surgery.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Nivolumab
- 2.Take Sacituzumab Govitecan (SG)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), sacituzumab govitecan
Drug routes
infusion
Endpoints
Primary: Primary Objective
Body systems
Oncology